South Africa's HIV/AIDS treatment program

NewsGuard 100/100 Score

The progress of South Africa's HIV/AIDS treatment program "so far is really a lesson in the power of balanced government and citizens' groups," columnist Tina Rosenberg writes in a New York Times opinion piece.

South Africa is "doing AIDS treatment on a mass scale," and "more than a quarter million South Africans -- more people than in any other nation -- are now taking antiretroviral drugs," she writes.

According to Rosenberg, "top officials can take little credit" because "[t]hey delayed the antiretroviral rollout, threw up obstacle after obstacle and have left large pots of money unspent."

Although "[s]ome regional governments ... have leapt at the chance to provide antiretrovirals," the "most important factor" in the progress of HIV/AIDS treatment programs in the country is the Treatment Action Campaign, which is "probably the world's most effective AIDS group," according to the opinion piece.

In addition, South African "courts have forced the government into action," Rosenberg writes. The South African government "should also be pushing the provinces that lag behind and encouraging South Africans to get tested and take their drugs," Rosenberg writes (Rosenberg, New York Times, 8/30).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Interferon-beta deficiency alters brain response in neuroHIV mouse model